Product Description
Atovaquone is used to treat Pneumocystis jiroveci [Pneumocystis carinii] pneumonia (PCP; type of pneumonia most likely to affect people with human immunodeficiency virus [HIV]) in teenagers and adults. Atovaquone is also used to prevent PCP in teenagers and adults who cannot take another medication used for prevention. Atovaquone is in a class of medications called antiprotozoal agents. It works by stopping the growth of certain types of protozoa that can cause pneumonia. (Sourced from: https://medlineplus.gov/druginfo/meds/a693003.html)
Mechanisms of Action: Pyrimidine Synthesis Inhibitor
Novel Mechanism: No
Modality: Small Molecule
Route of Administration: Oral
FDA Designation: None *
Approval Status: Approved
Approved Countries: Australia | Austria | Belgium | Brazil | Canada | Denmark | Dominican Republic | Estonia | Finland | France | Germany | Greece | Hong Kong | Italy | Japan | Lithuania | Luxembourg | Malaysia | Malta | Morocco | Netherlands | New Zealand | Norway | Pakistan | Peru | Portugal | Slovenia | South Africa | Spain | Sweden | Switzerland | Taiwan | Thailand | United Arab Emirates | United Kingdom | United States | Vietnam
Approved Indications: Pneumonia, Pneumocystis | Pneumonia | Malaria | Malaria, Falciparum
Known Adverse Events: Headache | Diarrhea | Abdominal Pain | Dizziness | Pain Unspecified | Oral Ulcer | Pruritus | Anorexia | Asthenia
Company: GlaxoSmithKline
Company Location: BRENTFORD MIDDLESEX X0 TW8 9GS
Company CEO: Emma Walmsley
Additonal Commercial Interests: None
Clinical Description
Countries in Clinic: United Kingdom
Active Clinical Trial Count: 2
Highest Development Phases
Phase 1: Malaria|Non-Small-Cell Lung Cancer
Trial |
Phase |
Trial Status |
Disease |
Primary Completion Date |
Probability of Success |
|---|---|---|---|---|---|
| ARCADIAN | P1 |
Completed |
Non-Small-Cell Lung Cancer |
2023-10-02 |
|
| MMV_SMC_19_02 | P1 |
Completed |
Malaria |
2022-03-18 |